Cystic Fibrosis Foundation
6931 Arlington Road
Bethesda
Maryland
20814
United States
Tel: 301-951-4422-Or-800-344-4823
Fax: 301-951-6378
Website: http://www.cff.org/
Email: info@cff.org
67 articles about Cystic Fibrosis Foundation
-
Cystic Fibrosis Foundation Funds Up to $15 Million to Prime Medicine to Pursue Gene Editing in CF
1/25/2024
Today, the Cystic Fibrosis Foundation announced that it will provide up to $15 million to Prime Medicine for preclinical research into gene editing for cystic fibrosis.
-
Sail Biomedicines Provides Update on Research with Cystic Fibrosis Foundation and Pioneering Medicines
1/5/2024
Sail Biomedicines, Inc. today provided an update on its research funded by the Cystic Fibrosis Foundation (CF Foundation), with preclinical data that suggest that Sail’s Endless RNA™ (eRNA™) may offer the potential to treat the 10%-15% of people with CF for whom existing treatments are not an option.
-
CF Foundation Invests Up to $9 Million in Arcturus Therapeutics to Develop a Messenger RNA Therapy
9/26/2023
The Cystic Fibrosis Foundation is investing up to $9 million in additional funds in Arcturus Therapeutics to test an inhaled messenger RNA (mRNA) therapy that could treat the underlying cause of cystic fibrosis in all people living with the disease, including those with two copies of rare and nonsense mutations.
-
Arcturus Therapeutics and Cystic Fibrosis Foundation Extend Agreement to Advance ARCT-032, an Investigational Messenger RNA (mRNA) Therapeutic to Treat Cystic Fibrosis
9/26/2023
Arcturus Therapeutics Holdings Inc. (the announced today that Arcturus and the Cystic Fibrosis Foundation (CF Foundation) have extended their ongoing agreement.
-
Cystic Fibrosis Foundation Announces Yvonne Massenburg as Next Chief People Officer
4/5/2023
The Cystic Fibrosis Foundation announced that Yvonne Massenburg will join the organization as its next Chief People Officer.
-
Nanite Inc. Receives Up to $2M Investment from CF Foundation to Explore a Novel Method to Deliver Genetic Therapies to the Lung
3/15/2023
Nanite Inc. announced today an investment from the Cystic Fibrosis Foundation of up to $2 million to develop gene delivery technology.
-
ReCode Therapeutics Announces Strategic Investment from the Cystic Fibrosis Foundation to Accelerate Development of Novel mRNA Therapy
1/10/2023
ReCode Therapeutics announced today that it will receive a strategic investment from the Cystic Fibrosis Foundation (CF Foundation) to develop ReCode’s inhaled mRNA-based therapeutic for people with cystic fibrosis (CF), including those with genotypes that do not respond to approved CFTR modulators.
-
Aridis Pharmaceuticals Receives Equity Investment from the Cystic Fibrosis Foundation
12/12/2022
Aridis Pharmaceuticals, Inc. today announced the Cystic Fibrosis Foundation invested $4.85 million in Aridis common stock on market terms under NASDAQ rules to support the ongoing development of AR-501, an inhalable broad-spectrum anti-infective currently under development for controlling debilitating chronic lung infections in cystic fibrosis (CF) patients.
-
Cystic Fibrosis Foundation Announces Irena Barisic as Next Chief Operating and Financial Officer
12/6/2022
The Cystic Fibrosis Foundation announced that Irena Barisic has been appointed the next Executive Vice President, Chief Operating and Financial Officer.
-
Cystic Fibrosis Foundation Invests $6M in Carbon Biosciences to Advance New Gene Therapy Approach for Cystic Fibrosis
6/21/2022
The Cystic Fibrosis Foundation announced its investment of $6 million in Carbon Biosciences to support the company‘s preclinical research into an innovative gene therapy approach for cystic fibrosis.
-
Cystic Fibrosis Foundation Launches Inaugural Golden Ticket Competition to Find the Next Genetic Therapies for CF
4/18/2022
Cystic Fibrosis Foundation Launches Inaugural Golden Ticket Competition to Find the Next Genetic Therapies for CF.
-
Bakar Labs and the Cystic Fibrosis Foundation Support Entrepreneurs to Develop New Genetic Therapies for CF
4/18/2022
Bakar Labs, the incubator at UC Berkeley's Bakar BioEnginuity Hub (BBH), announced today a unique collaboration with the Cystic Fibrosis Foundation to accelerate the application of new technologies for the treatment of cystic fibrosis.
-
CF Foundation Funds Expansion of Clinical Trial Program for Potential Nonsense Mutations Therapy
3/29/2022
Today, the Cystic Fibrosis Foundation announced an award to Eloxx Pharmaceuticals Inc. for up to $15.9 million in additional funding to support the expansion of its ongoing ELX-02 clinical program focused on developing therapies for people with CF who have nonsense mutations.
-
Eloxx Pharmaceuticals Announces Therapeutic Development Award from Cystic Fibrosis Foundation
3/29/2022
Eloxx Pharmaceuticals, Inc. today announced that the Company has received additional funding of a Therapeutic Development Award of up to $15.9 million from the CF Foundation to support the ongoing ELX-02 clinical program.
-
Cystic Fibrosis Foundation Invests in Felix Biotechnology as They Advance New Therapies Targeting Chronic Infections in Cystic Fibrosis
3/3/2022
Felix Biotechnology today announced it received a strategic investment from the Cystic Fibrosis Foundation as part of a Therapeutics Development Award.
-
Cystic Fibrosis Foundation Announces Steven Rowe, MD, as Next Chief Scientific Officer
1/26/2022
Dr. Steven Rowe will support mission to cure cystic fibrosis by leading the Foundation’s research strategy, focusing on genetic therapies.
-
Cystic Fibrosis Foundation Announces Investment in SalioGen Therapeutics to Fund Genetic Therapies Research
1/5/2022
The Cystic Fibrosis Foundation announced today that it has invested in SalioGen Therapeutics to support the company’s preclinical research into a novel genetic therapy for cystic fibrosis.
-
Peptilogics Receives Award from the Cystic Fibrosis Foundation to Investigate PLG0301 and PLG0206 as Potential Dual-Acting Treatments for Lung Infections Associated with Cystic Fibrosis
1/5/2022
Peptilogics today announced that the company received an award from the Cystic Fibrosis Foundation.
-
CF Foundation Awards Up to $5 Million to BiomX for Potential Phage Therapy
1/4/2022
Study reaffirms the Foundation’s commitment to advance solutions to the growing challenge of antibiotic resistance.
-
Pulmocide Receives Investment from the Cystic Fibrosis Foundation
12/6/2021
Pulmocide Ltd. today announced a $3.5 million investment from the Cystic Fibrosis Foundation for the development of opelconazole for lung transplant recipients.